Bildkälla: Stockfoto

BioArctic: Outlicenses PyroGlutamate-amyloid-beta antibody program to BMS - Redeye

Redeye endorses the news that BioArctic has signed a licensing agreement with BMS regarding BioArctic's PyroGlutamate-amyloid-beta antibody program and give our initial take.

Redeye endorses the news that BioArctic has signed a licensing agreement with BMS regarding BioArctic's PyroGlutamate-amyloid-beta antibody program and give our initial take.
Börsvärldens nyhetsbrev
ANNONSER